期刊
LANCET
卷 370, 期 9603, 页码 1923-1928出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(07)61815-7
关键词
-
资金
- Medical Research Council [MC_U122886351, G0600337, G0200585] Funding Source: Medline
- MRC [MC_U122886351, G0600337, G0200585] Funding Source: UKRI
- Medical Research Council [G0200585, G0600337, MC_U122886351] Funding Source: researchfish
Background The long-term durability of viral-load suppression provided by the three original antiretroviral drugs is not well characterised. We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure. Methods 7916 patients who started antiretroviral therapy with three or more drugs were followed up from the time that therapy started until the last viral-load measure. Extensive triple-class virological failure was defined by failure of three subclasses of nucleoside reverse transcriptase inhibitors, a non-nucleoside reverse transcriptase inhibitor, and a ritonavir-boosted protease inhibitor. Findings 167 patients developed extensive triple-class failure during 27 441 person-years of follow-up. The Kaplan-Meier estimate for the cumulative risk of extensive triple-class failure was 9.2% by 10 years (95% CI 5.0-13.4). There was evidence that this rate has decreased over time (adjusted hazard ratio 0 . 86 [0.77-0.96] per year more recent; p=0 . 006). Of the 167 patients with extensive triple-class failure, 101 (60%) subsequently had at least one viral load less than 50 copies per mL. The risk of death by 5 years from the time of extensive triple-class failure was 10 . 6% (2 . 4-18.8, nine deaths). Interpretation We have shown that extensive virological failure of the three main classes of drugs occurs slowly in routine clinical practice. This finding has implications for the planning of treatment programmes in developing countries, where additional drugs outside these classes are unlikely to be available for some time.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据